Md Saiful Islam Khan/iStock through Getty Photographs
Exelixis (NASDAQ:EXEL) reported outcomes from a Section 3 research for its drug Cabometyx, also referred to as cabozantinib, within the remedy of sufferers with sure neuroendocrine tumors.
The drugmaker stated the research met its main goal of exhibiting that sufferers who had been administered the drug confirmed “dramatic enchancment” in median progression-free survival. The drug was examined on two cohorts of sufferers, one with superior pancreatic neuroendocrine tumors and the opposite with superior extra-pancreatic neuroendocrine tumors.
The corporate offered the info on Monday on the 2023 European Society of Medical Oncology Congress in Spain.
Exelixis is presently engaged in a patent battle over Cabometyx with MSN Laboratories, which is searching for to place out a generic model of the product. The trial began on Monday.
Shares of Exelixis had been down 9% in early afternoon buying and selling Monday.